Good evening, readers. And apologies for the late send—we’ve had a busy few days.
We just wrapped up our first virtual Brainstorm Health conference. There’s no way that I can sum up the fascinating interviews, panels, discussions, and post-session write-ups in a single newsletter. We’ll be trickling through a whole bunch of the issues we addressed over the next few days (and for general coverage from our Fortune team, head right over here.)
But one of the main themes of this conference has centered on digital health and whether or not such such technologies can give a much-needed assist during the coronavirus pandemic.
The trouble is that these new resources, whether apps, better data-sharing, or better devices, are still guinea pigs. When it comes to contact tracing for COVID-19, “countries have just started to use it,” said Dr. David Feinberg of Google Health following a session on innovation and health care during the conference.
Coronavirus isn’t the beginning. But it has the potential to be the catalyst. That was a sentiment echoed by numerous panelists including former Food and Drug Administration (FDA) commissioner Margaret Hamburg and her fellow attendees Baxter International CEO Joe Almeida and GE Healthcare CEO Kieran Murphy for those who have chronic conditions outside of COVID.
“We need to create a safety net where people can feel protected,” said Almeida during the session. Murphy added that GE has “deployed real time data to show where such capacity exists and divert patients to there… There needs to be a market where we can deploy telemedicine.”
It’s an issue that speaks to the needs of chronic disease, rare disease, and underserved communities all in one. Whether telehealth can confront these ills is a much broader question we’ll be tackling for years.
Read on for the day’s news, and look to this space for more coverage of our conference.
Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy
DIGITAL HEALTH
Can wearables be key to detecting COVID? Amy McDonough of FitBit added more to the conversation about the intersection of COVID and wearable devices. "We are getting less steps. We are moving less throughout the day, but our amount of purposeful activity [exercise] is actually going up. And what that is resulting in is statistically significant decreases in things like resting heart rate," McDonough said on Wednesday. (Fortune)
INDICATIONS
Biogen surges on its Alzheimer's gamble. Shares of Biogen rose more than 4% after the company submitted an application for its experimental, and controversial, Alzheimer's drug aducanumab to the FDA. This treatment will prove a milestone for the FDA. On the one hand, there are no approved therapies for Alzheimer's. On the other, it's been difficult to balance efficacy and safety versus what could be a high cost for a drug for dementia, which afflicts millions of people every year.
Novavax spikes from a federal boost. Readers may know about the various treatments being tried out for COVID vaccines and therapeutics. Here's one you may not know that well. My colleague Jeff John Roberts about sums it up: "The government's decision to grant Novavax such a large contract is remarkable given that Novavax has never brought a drug to market, and because other firms that received money under the same program—known as Operation Warp Speed—include drug industry titans like Johnson & Johnson and Astra Zeneca." Sound familiar? (Fortune)
REQUIRED READING
A Fortune 500 CEO on why companies must take a stand on racism and social issues, by Lucinda Shen
How Rwanda is beating the U.S. in the fight against coronavirus, by David Z. Morris
Apple and Google's contact tracing system gains more participants across the globe, by Aaron Pressman
